TrialThe oncologist2013

Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.

Cristina Saura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.